|
Characteristic
|
No. of patients
|
%
|
|---|
|
No. of patients
|
36
|
100
|
|
Gender
| | |
|
Male
|
31
|
86.1
|
|
Female
|
5
|
13.9
|
|
Age, years
| | |
|
Median
|
56
| |
|
Range
|
26-77
| |
|
ECOG performance status
| | |
|
0
|
24
|
66.7
|
|
1
|
12
|
33.3
|
|
Hepatitis status
| | |
|
Hepatitis B
|
29
|
80.5
|
|
Hepatitis C
|
1
|
2.8
|
|
Non-B non-C
|
6
|
16.7
|
|
Baseline AFP > 10 μg/l
| | |
|
Yes
|
25
|
69.4
|
|
No
|
11
|
30.6
|
|
Tumour Burden
| | |
|
BCLC Stage B
|
28
| |
|
BCLC stage C
|
8
| |
|
Macroscopic vascular invasion
|
24
|
66.7
|
|
Extrahepatic disease
|
21
|
58.3
|
|
Prior therapy for HCC of any forms
|
29
|
80.6
|
|
Blood parameters (median, range):
| | |
|
Total bilirubin
|
16 (5–34) umol/l
| |
|
Albumin
|
39. (32–48) g/l
| |
|
Alanine transaminase
|
40 (18–140) iu/l
| |
|
Alkaline phosphatase
|
108 (52–434) iu/l
| |
|
AFP
|
82 (1–118712) ug/l
| |
|
INR
|
1.06 (0.89-1.26)
| |
|
Creatinine
|
82 (44–136) umol/l
| |
|
Glucose
|
5.4 (4.0-8.5) mmol/l
| |
|
Triglyceride
|
0.9 (0.5-2.0) mmol/l
| |
|
LDL cholesterol
|
2.65 (1.6-7.3) mmol/l
| |
|
HDL cholesterol
|
1.15 (0.7-2.5) mmol/l
| |
|
Total cholesterol
|
4.45 (3.0-8.9) mmol/l
| |
|
Prior systemic therapy
| | |
|
1 line
|
11
|
30.5
|
|
2 lines
|
1
|
2.8
|
|
3 lines
|
1
|
2.8
|
|
Prior local +/− regional therapy
| | |
|
Surgery
|
23
|
63.9
|
|
*Local ablation
|
4
|
11.0
|
|
Transarterial therapy
|
20
|
55.5
|
- *2 had radiofrequency ablation and 2 had percutaneous ethanol injection.
